These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 6915075)

  • 1. Mechanism of enhanced complement-dependent cytotoxicity of papain-treated lymphocytes: evidence for increased stability of classical pathway C3 convertase.
    Lublin DM; Grumet FC
    J Immunol; 1982 Feb; 128(2):866-70. PubMed ID: 6915075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
    Kievits F; Kijlstra A
    Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A complement-resistant HeLa cell line (T638) is blocked at the step of C3 deposition.
    Santi P; Joiner KA; Hammer CH; Frank MM; Tosi R
    J Immunol; 1987 May; 138(10):3385-91. PubMed ID: 2952716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation and deregulation of the fluid-phase classical pathway C3 convertase.
    Gigli I; Sorvillo J; Halbwachs-Mecarelli L
    J Immunol; 1985 Jul; 135(1):440-4. PubMed ID: 3158705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A covalent dimer of complement C4b serves as a subunit of a novel C5 convertase that involves no C3 derivatives.
    Masaki T; Matsumoto M; Yasuda R; Levine RP; Kitamura H; Seya T
    J Immunol; 1991 Aug; 147(3):927-32. PubMed ID: 1861081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation.
    Halili MA; Ruiz-Gómez G; Le GT; Abbenante G; Fairlie DP
    Biochemistry; 2009 Sep; 48(35):8466-72. PubMed ID: 19642650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase.
    Gigli I; Sorvillo J; Mecarelli-Halbwachs L; Leibowitch J
    J Exp Med; 1981 Jul; 154(1):1-12. PubMed ID: 7019379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein.
    Daha MR; van Es LA
    J Immunol; 1980 Nov; 125(5):2051-4. PubMed ID: 6903579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps.
    Ollert MW; Kadlec JV; David K; Petrella EC; Bredehorst R; Vogel CW
    J Immunol; 1994 Sep; 153(5):2213-21. PubMed ID: 8051421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding of C-reactive protein to nucleated cells leads to complement activation without cytolysis.
    Berman S; Gewurz H; Mold C
    J Immunol; 1986 Feb; 136(4):1354-9. PubMed ID: 3944459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of chrysotile asbestos fibres with the complement system.
    Saint-Remy JM; Cole P
    Immunology; 1980 Oct; 41(2):431-7. PubMed ID: 6904360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for restriction of the ability of complement to lyse homologous erythrocytes.
    Houle JJ; Hoffmann EM
    J Immunol; 1984 Sep; 133(3):1444-52. PubMed ID: 6430999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of the classical pathway C3 convertase (EAC4b2a) by proteolytic enzymes.
    Loos M; Heinz HP
    Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():67-74. PubMed ID: 6375257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the activity of the classical complement pathway C3 convertase by surface-bound C3 or C5.
    Strunk RC; Giclas PC
    J Immunol; 1980 Feb; 124(2):520-6. PubMed ID: 7356706
    [No Abstract]   [Full Text] [Related]  

  • 18. Human fibrinogen bound to Streptococcus pyogenes M protein inhibits complement deposition via the classical pathway.
    Carlsson F; Sandin C; Lindahl G
    Mol Microbiol; 2005 Apr; 56(1):28-39. PubMed ID: 15773976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxoplasma gondii: mechanism of resistance to complement-mediated killing.
    Fuhrman SA; Joiner KA
    J Immunol; 1989 Feb; 142(3):940-7. PubMed ID: 2643665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptors on guinea-pig erythrocytes specific for cell-bound fourth component of human complement (C4).
    Wilson AB; Prichard-Thomas S; Lachmann PJ; Coombs RR
    Immunology; 1980 Feb; 39(2):195-202. PubMed ID: 7380467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.